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Key Points
•Use of NOACs rather
than VKAs was associ-
ated with lower risks of
all-cause death and all
bleeding categories in
AF patients.
• Rate of death was
highest in patients with
major bleeding and
higher in patients with
nonmajor bleeding than
in those with no
bleeding.
In atrial fibrillation (AF), lower risks of death and bleeding with non-vitamin-K oral
anticoagulants (NOACs) were reported in meta-analyses of controlled trials, but whether
these findings hold true in real-world practice remains uncertain. Risks of bleeding and
death were assessed in 52 032 patients with newly diagnosed AF enrolled in GARFIELD-AF
(Global Anticoagulant Registry in the FIELD–Atrial Fibrillation), a worldwide prospective
registry. Baseline treatment was vitamin K antagonists (VKAs) with or without antiplatelet
(AP) agents (VKA 6 AP) (20 151; 39.3%), NOACs 6 AP agents (14 103; 27.5%), AP agents only
(10 748; 21.0%), or no antithrombotics (6219; 12.1%). One-year follow-up event rates (95%
confidence interval [CI]) of minor, clinically relevant nonmajor (CRNM), and major
bleedings were 2.29 (2.16-2.43), 1.10 (1.01-1.20), and 1.31 (1.21-1.41) per 100 patient-years,
respectively. Bleeding risk was lower with NOACs than VKAs for any bleeding (hazard
ratio (HR) [95% CI]), 0.85 [0.73-0.98]) or major bleeding (0.79 [0.60-1.04]). Compared with
no bleeding, the risk of death was higher with minor bleeding (adjusted HR [aHR], 1.53
[1.07-2.19]), CRNM bleeding (aHR, 2.59 [1.80-3.73]), and major bleeding (aHR, 8.24 [6.76-10.04]).
The all-cause mortality rate was lower with NOACs than with VKAs (aHR, 0.73 [0.62-0.85]).
Forty-five percent (114) of all deaths occurred within 30 days, and 40% of these were from
intracranial/intraspinal hemorrhage (ICH). The rates of any bleeding and all-cause death
were lower with NOACs than with VKAs. Major bleeding was associated with the highest risk
of death. CRNM bleeding and minor bleeding were associated with a higher risk of death
compared to no bleeding. Death within 30 days after a major bleed was most frequently
related to ICH. This trial was registered at www.clinicaltrials.gov as #NCT01090362.
Introduction
Oral anticoagulation (OAC) reduces the risk of death and stroke/systemic embolism (SE) in atrial
fibrillation (AF), at the cost of an increased risk of bleeding.1-3 In AF, the rates and prognostic impact of
bleeding have been described in controlled randomized trials (RCTs) and retrospective population-
based studies.4-10 They were rarely analyzed in prospective registries.11 Non-vitamin-K oral
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anticoagulants (NOACs) have a better safety profile than vitamin K
antagonists (VKAs) in RCTs and meta-analysis.12-16 Whether
findings from RCTs are confirmed in a large prospective registry
reflecting daily routine practice worldwide remains to be shown.
The aim of our study was to (1) describe the incidence, sites,
severity, predictors, and outcomes of bleeding and (2) assess the
safety profiles of NOACs vs VKAs at 1 year follow-up in 52 080
patients with newly diagnosed AF enrolled in the prospective Global




GARFIELD-AF is the largest fully recruited multinational prospective
registry in AF.17 Patients were prospectively recruited between
March 2010 and August 2016 in .1000 investigational sites
(identified nationally as representative) in 35 countries. Adults
$18 years were eligible for inclusion if they were diagnosed with AF
within 6 weeks of study entry. Identification of patients was
according to standard local practice, and patients were required
to have $1 unspecified investigator-defined risk factor for stroke.
Patients were enrolled prospectively and consecutively at sites that
reflected the diversity of care settings in each participating country
(office-based practice; hospital departments [neurology, cardiol-
ogy, geriatrics, internal medicine, and emergency]; anticoagulation
clinics; and general or family practice).17,18
Ethics statement
Independent ethics committee and hospital-based institutional
review board approvals were obtained. The registry was conducted
in accordance with the principles of the Declaration of Helsinki,
local regulatory requirements, and the International Conference on
Harmonization–Good Pharmacoepidemiologic and Clinical Prac-
tice guidelines. Written informed consent was obtained from all
study participants.
Procedures and outcome measures
Patients who were taking anticoagulants prior to study enrolment
were excluded from this analysis. Baseline characteristics collected
at study entry included medical history, care setting, type of AF, date
and method of diagnosis of AF, symptoms, antithrombotic treatment
(VKA, NOAC, and antiplatelet [AP] treatment), and cardiovascular
drugs. The risk profile for death, stroke/SE, and bleeding was
assessed with the congestive heart failure, hypertension, age $75
years, diabetes mellitus, prior stroke, TIA, or thromboembolism,
vascular disease, age 65-74 years, sex category (CHA2DS2-VASc)
and hypertension (uncontrolled systolic blood pressure .160 mm
Hg), abnormal renal or liver function, previous stroke, bleeding
history or predisposition, Labile international normalized ratios,
elderly, and concomitant drugs or alcohol excess (HAS-BLED)17-19
and GARFIELD-AF risk calculator.20 We used standardized
definitions for clinical events.17,18 Bleeding severity was defined
as major, clinically relevant nonmajor (CRNM), and minor bleeding
according to the International Society on Thrombosis and
Haemostasis scale17,18 (details in supplemental Material). Data
for this report were extracted from the study database on 19
November 2018.
Collection of follow-up data using an electronic case report (eCRF)
form occurred at 4 monthly intervals up to 24 months or until death
or loss to follow-up, whichever occurred first. Submitted data were
examined for completeness and accuracy by the coordinating
center (Thrombosis Research Institute, London, United Kingdom),
and data queries were sent to study sites. In accordance with the
study protocol, 20% of all eCRFs were monitored against source
documentation.21
Statistical analysis
Continuous variables were expressed as medians and interquartile
ranges and categorical variables as frequencies and percentages.
As studies with large sample sizes tend to produce statistically
significant findings in the presence of clinically irrelevant differ-
ences, no formal statistical tests were performed for the baseline
tables.
For descriptive purposes, such as baseline tables where patients
must be assigned to only 1 group, the worst bleed category that the
patient experienced is assigned. Otherwise, the first occurrence of
each bleed type is used.
Rates are presented as person-years with 95% confidence intervals
for the first occurrence of the clinical outcomes. The timing of
events by baseline treatment started at the day of enrolment;
survival after bleeding started on the day of bleed.
All-cause mortality rates per 100 person-years for the different
types of bleeds, including no bleed, were calculated using a different
method. All patients started as “no bleeds” until they had their first
worst bleed. At this point, time began for the corresponding bleed
group and then followed up for a total of 365 days. A death was
assigned to the period in which the event occurred. Thus, patients
with bleeds contribute to the rate for both “no bleeds” and their
worst bleed category.
Hazard ratios (HRs) of the risk of all-cause mortality for each type of
bleed were calculated with Cox proportional hazards model, using
bleeding by type as time-dependent covariates. To account for
within-patient variance, given the occurrence of multiple bleeds in
the same patient, clustering was used. Adjusted HRs (aHRs) used
factors previously derived for all-cause mortality in the GARFIELD-
AF study.22 Single imputation was applied for missing data.
For predictors of major bleeding (vs those without a major bleed),
a LASSO (least absolute shrinkage and selection operator) model
was used for a single imputation data set. The HRs and
corresponding standard errors for the final model of major bleeding
were derived across 5 multiple imputed data sets that had been
generated applying the Markov chain Monte Carlo (MCMC)
methodology.
Comparative effectiveness of treatments was calculated using the
subset of patients from cohorts 3 to 5 (when NOACs were
available), with a CHA2DS2-VASc $2 in men and $3 in women,
without OAC treatment prior to enrolment and who were prescribed
a VKA or a NOAC at baseline. HRs for NOACs vs VKAs were
obtained using a Cox proportional hazards model using a propensity
method of overlap weighting to balance covariates in the
population.23 The applied method overlaps weights and optimizes
the efficiency of comparisons by defining the population with the
most overlap in the covariates between treatment groups. This
scheme eliminates the potential for outlier weights by avoiding
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a weight based on a ratio calculation using values bounded by 0 and
1. Thus, when using overlap weights, many of the concerns
regarding the assessment and the trimming of the weights are
eliminated. Covariates evaluated in the weighting scheme included
demographic characteristics, medical history, and other character-
istics (details in supplemental Material). Treatment was defined as
the first treatment received at the time of enrolment, approximating
“intention to treat.” Patients with missing values were not removed
from the study; single imputation was applied for the comparative
effectiveness analysis.
Analyses were performed using R version 3.5.3 (libraries include,




Following the exclusion of patients with unavailable follow-up, the
study population comprised all 52 032 patients prospectively
recruited in the GARFIELD-AF registry with at least 1 year of
follow-up, of whom 49702 had no bleed, 1098 suffered only
a minor bleed (2.29 [2.16-2.43]), 524 a minor or CRNM bleed (1.10
[1.01-1.20]), and 622 with $1 major bleed (1.31 [1.21-1.41]) per
100 patient-years, totaling 2330 patients with$1 bleeding episode,
including 86 unclassified bleeds.
Patients who bled were older, tended to have higher blood
pressure and lower body weight (major bleeding patients), and
more frequently had a history of hypertension (major and CRNM
bleeding patients) than patients who did not bleed. Those who
bled had a more frequent history of bleeding, vascular disease,
stenting, stroke, diabetes (major bleeding patients), and moderate
to severe chronic kidney disease (CKD). They were more often
white and less often Asian. The pattern of AF (permanent,
persistent, paroxysmal, or unclassified) at the time of recruitment
was similar across the different subgroups. The risk profiles for
death, stroke/SE, and bleeding as assessed by the GARFIELD-AF
risk calculator20 were higher in all patients who bled than in no-
bleeding patients.
Overall, VKAs with or without AP agents (VKA 6 AP) (n 5 20151,
39.3%) were more commonly prescribed than NOACs with or
without AP agents (NOAC 6 AP) (n 5 14103, 27.5%), AP
monotherapy (n 5 10478, 21.0%), or no treatment (n 5 6219,
12.1%). Bleeding irrespective of its severity was numerically more
commonly observed in VKA-treated patients than in NOAC-treated
patients, AP-treated patients, and no-treatment patients (Figure 1).
The prescription of OAC combined with AP agents tended to be
more frequent in patients who bled (Table 1).
VKA-treated patients who suffered a major bleeding tended to
have a lower median time in therapeutic range (TTR) value (43.1
[interquartile range, 21.5-71.3]) than with CRNM (49.3 [23.5-73.1])
and minor bleeding (51.3 [26.2-72.3]). In NOAC-treated patients,
the rate of recommended dosing tended to be lower in those who
suffered major bleeding (66.4%) compared with CRNM bleeding
(71.8%), minor bleeding (72.6%), and NOAC-treated patients who
did not bleed (73%).
The risk profiles of patients prescribed VKA 6 AP or NOAC 6 AP
were not significantly different as assessed with the common risk
assessment tools (CHA2DS2-VASc and HAS-BLED). However, the
GARFIELD-AF risk calculator showed a gradual increase in the risk
of death, stroke/SE, and bleeding across the subgroups, from the
no-bleed subgroup to the major bleeding subgroup. NOAC 6
AP–treated patients tended to have more frequently a paroxysmal
AF pattern (supplemental Table 1).
Sites, precipitants, and management of bleeding
Gastrointestinal bleeding and intracranial/intraspinal hemorrhage
(ICH) were the most frequent bleeding and accounted for 40% and
24.8% of all major bleeds respectively; 249 cases and 154 cases;
0.51 (0.45 to 0.58) and 0.31 (0.27 to 0.37) per 100-patient-year
respectively. The most frequent minor and CRNM bleeding sites
were eyes, ears, nose, and skin related followed by gastrointestinal
and genitourinary bleeds. Transfusion was necessary in 51% of
cases of major bleeding (Table 2).
Bleeding rates and predictors of bleeding
The highest unadjusted rates of major bleeding were observed with
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Figure 1. Bleeding rates per 100 person-years
according to antithrombotic patterns at baseline.




 http://ashpublications.org/bloodadvances/article-pdf/5/4/1081/1800729/advancesadv2020003560.pdf by guest on 05 M
arch 2021
Table 1. Baseline characteristics by bleeding occurrence and severity
Baseline characteristics
Bleeding occurrence and severity
Major bleed (n 5 622) CRNM bleed (n 5 524) Minor (n 5 1098) No bleed (n 5 49702)
Female sex, n (%) 316 (50.8) 225 (42.9) 498 (45.4) 21 913 (44.1)
Age, median (Q1;Q3), y 76.0 (70.0;82.0) 75.0 (68.0;81.0) 74.0 (66.0;79.0) 71.0 (62.0;78.0)
Ethnicity, n (%)
White 430 (71.4) 406 (81.4) 778 (75.5) 30 338 (62.5)
Hispanic/Latino 36 (6.0) 22 (4.4) 41 (4.0) 3293 (6.8)
Asian 123 (20.4) 63 (12.6) 185 (18.0) 13 883 (28.6)
Afro-Caribbean/mixed/other 13 (2.2) 8 (1.6) 26 (2.5) 1021 (2.1)
BMI, median (Q1;Q3), kg/m2 26.5 (23.3;31.0) 27.5 (24.4;30.9) 27.0 (24.2;31.2) 26.9 (23.9;30.7)
Systolic blood pressure, median (Q1;Q3), mm Hg 133.0 (120.0;145.0) 135.0 (120.0;145.0) 134.0 (120.0;148.0) 130.0 (120.0;145.0)
Diastolic blood pressure, median (Q1;Q3), mm Hg 80.0 (70.0;87.5) 80.0 (70.0;89.0) 80.0 (70.0;88.0) 80.0 (70.0;88.0)
Pulse, median (Q1;Q3), bpm 88.0 (72.0;110.0) 88.0 (71.0;112.0) 84.0 (70.0;110.0) 84.0 (70.0;105.0)
Type of atrial fibrillation, n (%)
Permanent 68 (10.9) 76 (14.5) 129 (11.7) 6345 (12.8)
Persistent 84 (13.5) 77 (14.7) 148 (13.5) 7439 (15.0)
Paroxysmal 146 (23.5) 136 (26.0) 292 (26.6) 13 709 (27.6)
New onset (unclassified) 324 (52.1) 235 (44.8) 529 (48.2) 22 203 (44.7)
Care setting specialty at diagnosis, n (%)
Internal medicine/neurology/geriatrics 146 (23.5) 125 (23.9) 226 (20.6) 9933 (20.0)
Cardiology 370 (59.5) 290 (55.3) 652 (59.4) 32 826 (66.1)
Primary care/general practice 106 (17.0) 109 (20.8) 220 (20.0) 6937 (14.0)
Care setting location at diagnosis, n (%)
Hospital 343 (55.1) 275 (52.5) 598 (54.5) 29 085 (58.5)
Office/anticoagulation clinic/thrombosis center 168 (27.0) 158 (30.2) 335 (30.5) 15 225 (30.6)
Emergency room 111 (17.8) 91 (17.4) 165 (15.0) 5385 (10.8)
Medical history, n (%)
Heart failure 144 (23.2) 130 (24.8) 247 (22.5) 11 201 (22.5)
Acute coronary syndromes 101 (16.3) 64 (12.2) 155 (14.2) 5208 (10.5)
Vascular disease* 199 (32.2) 149 (28.5) 317 (29.0) 12 129 (24.6)
Carotid occlusive disease 37 (6.0) 17 (3.3) 40 (3.7) 1445 (2.9)
VTE 19 (3.1)) 24 (4.6) 35 (3.2) 1274 (2.6)
Prior stroke/TIA/SE 88 (14.2) 75 (14.4) 152 (13.9) 5514 (11.2)
Prior bleeding 40 (6.5) 27 (5.2) 60 (5.5) 1186 (2.4)
Hypertension 492 (79.4) 405 (77.4) 825 (75.1) 37 823 (76.3)
Hypercholesterolemia 281 (46.1) 240 (47.3) 490 (45.8) 19 917 (41.4)
Diabetes 177 (28.5) 122 (23.3) 228 (20.8) 10 998 (22.1)
Cirrhosis 7 (1.1) 3 (0.6) 5 (0.5) 279 (0.6)
Moderate to severe CKD 138 (22.9) 102 (20.0) 186 (17.6) 4915 (10.3)
Dementia 12 (1.9) 9 (1.7) 19 (1.7) 723 (1.5)
Heavy alcohol consumption 10 (1.9) 8 (1.9) 27 (3.0) 979 (2.3)
Current smoker 54 (9.5) 26 (5.5) 81 (8.2) 5031 (11.1)
Treatment, n (%)
NOAC 6 AP 160 (26.3) 148 (28.8) 307 (28.2) 13 488 (27.5)
BMI, body mass index; bpm, beats per minute; Q, quartile; TIA, transient ischemic attack.
*Defined as peripheral artery disease and/or coronary artery disease.
†The risk factor “labile international normalized ratios” is not included in the HAS-BLED score, as it is not collected at baseline. As a result, the maximum HAS-BLED score at baseline is 8 points
(not 9).
‡The risk of mortality within 1 year.
§The risk of nonhemorrhagic stroke/SE within 1 year.
||The risk of major bleeding within 1 year.
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and NOACs and AP agents (2.08 [1.57-2.76]) per 100 person-
years (Figure 1; supplemental Table 2). The most potent predictors
were age (HR, 1.23 [1.18-1.29] per 5-year increment), VKAs vs
NOACs (HR, 1.38 [1.09-1.75]), combination therapy with an OAC
plus AP agent (NOAC 1 AP vs NOAC: HR, 1.78 [1.26-2.51]; VKA
1 AP vs VKA: HR, 1.53 [1.20-1.95]), moderate to severe CKD (HR,
1.72 [1.41-2.10]), history of bleeding (HR, 2.38 [1.72-3.30]),
baseline heart rate (HR, 1.02 [1.01-1.04] per 5-beat increment),
and diabetes (HR, 1.26 [1.05-1.50]), and all were significant
predictors of major bleeding. Asian ethnicity was an independent
Table 1. (continued)
Baseline characteristics
Bleeding occurrence and severity
Major bleed (n 5 622) CRNM bleed (n 5 524) Minor (n 5 1098) No bleed (n 5 49702)
VKA 6 AP 311 (51.1) 247 (48.1) 529 (48.7) 19 064 (38.9)
AP agent only 72 (11.8) 72 (14.0) 147 (13.5) 10 457 (21.3)
None 66 (10.8) 46 (9.0) 104 (9.6) 6003 (12.2)
AP treatment (alone or in combination) 222 (36.5) 176 (34.3) 359 (33.0) 17 321 (35.3)
CHA2DS2-VASc score, median (Q1;Q3) 4.0 (3.0;5.0) 4.0 (3.0;5.0) 3.0 (2.0;5.0) 3.0 (2.0;4.0)
HAS-BLED score, median (Q1;Q3)† 2.0 (1.0;2.0) 2.0 (1.0;2.0) 2.0 (1.0;2.0) 1.0 (1.0;2.0)
GARFIELD death score, median (Q1;Q3)‡ 4.4 (2.5;7.8) 3.9 (2.2;6.9) 3.3 (1.7;6.5) 2.6 (1.4;4.8)
GARFIELD stroke score, median (Q1;Q3)§ 1.2 (0.9;1.8) 1.1 (0.8-1.7) 1.0 (0.7;1.6) 0.9 (0.6;1.4)
GARFIELD bleeding score, median (Q1;Q3)|| 1.5 (1.0;2.3) 1.4 (0.9-2.0) 1.3 (0.8;1.9) 1.0 (0.6;1.5)
BMI, body mass index; bpm, beats per minute; Q, quartile; TIA, transient ischemic attack.
*Defined as peripheral artery disease and/or coronary artery disease.
†The risk factor “labile international normalized ratios” is not included in the HAS-BLED score, as it is not collected at baseline. As a result, the maximum HAS-BLED score at baseline is 8
points (not 9).
‡The risk of mortality within 1 year.
§The risk of nonhemorrhagic stroke/SE within 1 year.
||The risk of major bleeding within 1 year.
Table 2. Sites, precipitants, and management of bleeding per bleeding types
Major (n 5 622) CRNM (n 5 524) Minor (n 5 1098) Unknown (n 5 86) Total (n 5 2330)
Site of bleed, n (%)
Eyes ears nose skin 33 (5.3) 192 (36.6) 494 (45) 30 (34.9) 749 (32.1)
Gastrointestinal tract 249 (40) 112 (21.4) 188 (17.1) 21 (24.4) 570 (24.5)
Genitourinary 28 (4.5) 116 (22.1) 160 (14.6) 11 (12.8) 315 (13.5)
Thorax and lungs 6 (1) 18 (3.4) 50 (4.6) 3 (3.5) 77 (3.3)
Intracranial/intraspinal 154 (24.8) 154 (6.6)
Other critical sites 42 (6.8) 42 (1.8)
Surgery or access 8 (1.3) 8 (1.5) 15 (1.4) 31 (5.6)
Other 77 (12.4) 67 (12.8) 171 (15.6) 14 (16.3) 329 (14.1)
Unknown 25 (4) 11 (2.1) 20 (1.8) 7 (8.1) 63 (2.7)
Bleeding precipitant, n (%)
Spontaneous 337 (54.2) 346 (66) 687 (62.6) 20 (23.3) 1390 (59.6)
Trauma related (nonsurgical) 68 (10.9) 45 (8.6) 93 (8.5) 7 (8.1) 213 (9.1)
Noncardiac surgery 32 (5.1) 30 (5.7) 22 (2) 1 (1.2) 8 (0.3)
Cardiac surgery 10 (1.6) 2 (0.4) 4 (0.4) 16 (0.6)
Unknown 175 (28.1) 101 (19.3) 292 (26.6) 58 (67.4) 626 (26.8)
Intervention required for bleed, n (%)
Surgical 132 (21.2) 58 (11.1) 33 (3) 3 (3.5) 226 (9.6)
Medical 352 (56.6) 227 (43.3) 205 (18.7) 19 (22.1) 803 (34.4)
None 88 (14.1) 233 (44.5) 833 (75.9) 38 (44.2) 1192 (51.1)
Transfusion
Yes 317 (51) 317 (13.6)
None 226 (36.3) 511 (97.5) 1091 (99.4) 66 (76.7) 1894 (59.8)
Unknown 79 (12.7) 13 (2.5) 7 (0.6) 20 (23.3) 119 (5.1)
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predictor of reduced risk of bleeding (HR, 0.77 [0.62-0.96])
(Table 3).
Death rates
In patients in whom bleeding was classified, all-cause death occurred
in 253 (11%) patients. Of those with a bleed, 163 out of 622 (26.2%)
died after major bleeding, 35 out of 524 (6.7%) died after CRNM
bleeding, and 56 out of 1098 (5.1%) died after minor bleeding. Most
deaths occurred within the first 30 days. Seventy-eight patients (31%)
died within the first day, 114 (45%) within 30 days, and 140 (55%)
after 30 days, explaining the initial abrupt decrease in the event-free
survival curve after major bleeding. The landmark analysis showed that
after 30 days, the survival curve for major bleeding continued to diverge
from the survival curves of minor and CRNM bleeding (Figure 2). Most
of these early deaths occurred after major bleeding (103/114), most
frequently after ICH (46 in 103 deaths within 30 days of major
bleeding).
The rates of all-cause mortality per 100 patient-years were 4.00 (3.82-
4.17) in no bleeding, 5.3 (4.1-6.9) in minor bleeding, 7.0 (5.0-9.8) in
CRNM bleeding, and 34.4 (29.5 to 40.1) in major bleeding. After
adjustment on a large variety of variables, the HR of all-cause mortality
was higher in all 3 categories of bleeding compared with no-bleeding
patients, respectively (aHR, 1.53 [1.07-2.19], 2.59 [1.80-3.73], and
8.24 [6.76-10.04] for minor, CRNM, and major bleeding) (Figure 3).
The death rates after major bleeding occurring under NOACs or
VKAs were not significantly different (NOAC 6 AP, 29.2 [21.3-
40.1] vs VKA 6 AP, 34.3 [27.6-42.7]) per 100 person-years (P 5
.483). The rates of all-cause death and cardiovascular death were
2.4-fold and 5.3-fold higher, respectively, after intracranial com-
pared with extracranial hemorrhage (supplemental Table 3).
Causes of death
In patients who died after a bleed, the cause of death was
cardiovascular in 99 patients (39%), mostly from ICH (53; 20.9%)
and less often from heart failure (15; 5.9%), sudden death (10;
3.9%), or ischemic stroke (9; 3.5%). The cause was noncardio-
vascular in 113 patients (44.5%) and included cancer (30; 11.8%),
respiratory failure (23; 9.1%), infection/sepsis (14; 5.5%), renal
failure (6; 2.4%), or miscellaneous (40; 15.7%). The cause of death
was undetermined in 42 patients (16.5%) (Table 4).
Comparative effectiveness analysis
This analysis was run on a subset of 19 640 patients from cohorts
3 to 5 (when NOACs were available) without OAC treatment prior
Table 3. Predictors of major bleeding
Description x2 P HR (95% CI)*
Age,y 82.57 ,.0001 1.23 (1.18-1.29)
Comparisons of antithrombotic strategies 62.25 ,.0001
AP vs NOAC 0.71 (0.52-0.96)
NOAC 1 AP vs NOAC 1.78 (1.26-2.51)
VKA vs NOAC 1.38 (1.09-1.75)
VKA 1 AP vs VKA 1.53 (1.20-1.95)
Moderate or severe CKD 28.54 ,.0001 1.72 (1.41-2.10)
History of bleeding 27.22 ,.0001 2.38 (1.72-3.30)
Pulse (per 5 bpm) 9.17 .003 1.02 (1.01-1.04)
Diabetes 6.43 .011 1.26 (1.05-1.50)
Asian vs not Asian 5.66 .018 0.77 (0.62-0.96)
Height per 5 (cm) 5.27 .022 0.95 (0.91-0.99)
Carotid occlusive disease 3.88 .049 1.41 (1.00-1.98)
Vascular disease 3.49 .061 1.19 (0.99-1.43)
CI, confidence interval.
*Adjusted for country of enrolment, cohort of enrolment, sex, age, race/ethnicity, type of
AF, care setting, specialty, heart failure, acute coronary syndromes, vascular disease,
carotid occlusive disease, prior stroke/TIA/SE, prior bleeding, VTE, hypertension, hypercho-
lesterolemia, diabetes, cirrhosis, moderate to severe CKD, dementia, hyperthyroidism,
hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, baseline
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Figure 2. Survival curves after bleeding. (A) Survival curves after minor, clinically relevant nonmajor and major bleeding at 1 year (where bleed type is defined by the worst
bleed type). (B) Landmark analysis from day 30 until a year from bleed.
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to enrolment who received at baseline either NOACs (9870; 50.3%)
or VKAs (9770; 49.7%). The rates of any-event, all-cause death and
all bleeding types were lower in NOAC-treated patients than in
VKA-treated patients (Tables 5 and 6).
The HR for any bleeding was significantly lower with NOAC 6 AP
than VKA6 AP (aHR, 0.85 [0.73-0.98]) and substantially (although
not significantly) lower for major bleeding (aHR, 0.79 [0.60-1.04]).
The HR for ICH (aHR, 0.78 [0.42-1.43]) was in the same range as
for major bleeding but with a low statistical power due to a low rate
of events. The risk of death to was significantly lower with NOAC6
AP than with VKA 6 AP (aHR, 0.73 [0.62-0.85]) (Tables 5 and 6).
Discussion
We found that NOAC use, either alone or combined with AP
agents, was associated with a lower risk of any bleeding or major
bleeding compared with VKAs, used either alone or combined with
AP agents. The risk of ICH was also reduced with NOACs use to
than same extent as major bleeding, though the reduction was non-
significant. Use of VKAs rather than NOACs was among the
strongest independent predictor of major bleeding and any
bleeding, along with age, history of bleeding, moderate to severe
CKD, as well as combination therapy with OACs and AP agents,
which is still widely used in this population (7350 patients [14%]).
Asian ethnicity was a predictor of a reduced risk of bleeding. Higher
risks of bleeding and ICH in Asians compared with non-Asians were
reported mostly in ancillary analyses of RCTs testing NOACs vs
VKAs.24-27 This discrepancy is related to the different nature of
RCTs and registry populations. Our earlier reports showed that
Asians had a lower baseline risk profile, with younger age and lower
rates of comorbidities compared with non-Asians.28 In addition, AP
agents and VKAs remain widely prescribed in several Asian
countries in whom target international normalized ratio in VKA-
treated patients is lower than in non-Asian countries. This results in
a lower risk of bleeding compared with non-Asian patients, yet with
no excess risk of stroke/SE.29-31
Previous reports derived from RCTs, retrospective population-
based registries, health care databases, or prospective regis-
tries deliver a common message, though with some degree of
heterogeneity across reports. Meta-analyses of RCTs show that
NOAC use is associated with a lower risk of stroke/SE, ICH, and
death than VKA use,16,32,33 with some heterogeneity across
NOACs.33 The message about major bleeding is less consistent.
A lower risk of major bleeding was reported in Hicks meta-analysis
that included phase 2 trials data in addition to all phase 3 RCTs,32
but neither in Ruff meta-analysis16 nor in Tereshchenko network
meta-analysis.33 A lower risk of ICH was reported in Ruff and Hicks
meta-analyses.16,32 In Tereshchenko meta-analysis, ICH was
a component of the definition of major bleeding.33
In retrospective analyses of population-based or health care
databases, heterogeneity was also found across NOAC subtypes
in regard to risks of major bleeding and ICH. Major bleeding risk was
found reduced in 2 analyses34,35 and ICH in 3.34-36 All 3 studies
tended to show that apixaban and dabigatran had a more favorable
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Figure 3. HRs for the risk of all-cause mortal-
ity according to type of bleeding. Adjusted for
factors previously derived for all-cause mortality in
the GARFIELD-AF study (age, treatment, CHF,
BMI, sex, race, type of AF, current smoker, heavy
alcohol use, diabetic, moderate to severe CKD, hy-
pertension, history of bleeding, vascular disease,
prior stroke/SE, or TIA). Bleed type was set as
a time-dependent covariate.
Table 4. Causes of death after bleeding
All-cause mortality Major CRNM Minor Total
Cardiovascular, n (%)
Myocardial infarction 4 (1.6) 1 (0.4) 0 (0) 5 (2.0)
Intracranial hemorrhage 53 (20.9) 53 (20.9)
Ischemic stroke 4 (1.6) 3 (1.2) 2 (0.8) 9 (3.5)
CHF 5 (2.0) 3 (1.2) 7 (2.7) 15 (5.9)
Sudden death 3 (1.2) 3 (1.2) 4 (1.6) 10 (3.9)
Miscellaneous 4 (1.6) 1 (0.4) 2 (0.8) 7 (2.7)
Total cardiovascular 70 (27.5) 13 (5.1) 16 (6.3) 99 (38.9)
Noncardiovascular, n (%)
Respiratory failure 12 (4.7) 5 (2.0) 6 (2.4) 23 (9.0)
Malignancy 13 (5.1) 8 (3.1) 9 (3.5) 30 (11.8)
Renal 2 (0.8) 1 (0.4) 3 (1.2) 6 (2.4)
Infection/sepsis 7 (2.7) 3 (1.2) 4 (1.6) 14 (5.5)
Miscellaneous 36 (14.2) 1 (0.4) 3 (1.2) 40 (15.7)
Total noncardiovascular 70 (27.5) 18 (7.1) 25 (9.8) 113 (44.5)
Unknown 23 (9.0) 3 (1.2) 16 (6.3) 42 (16.5)
Total 163 (64.2) 34 (13.4) 57 (22.4) 254




 http://ashpublications.org/bloodadvances/article-pdf/5/4/1081/1800729/advancesadv2020003560.pdf by guest on 05 M
arch 2021
registry, the risk of major bleeding and ICH rates was not
significantly different between NOACs and VKAs use.37
These differences may be inherent to the varied populations
analyzed in these reports. Baseline characteristics differ in RCTs
compared with cohort studies and prospective registries. The
quality of retrospective analyses depends on the completeness of
data collection. In addition, the outcomes are affected by the impact
of recall bias and survivorship bias.38 In addition, differences in code
schemas used to assess rates and severity of bleeding may result in
marked differences, even from analyses of the same database.39
Prospective registries provide a more robust model for collecting
data and outcomes. The prospective nature of GARFIELD-AF
registry as well as the use of the same bleeding scale (International
Society on Thrombosis and Haemostasis) as in RCTs may explain
the differences between our study and previous analyses.
The second important finding of this study is the confirmation that
NOAC use either alone or combined with AP agents was
associated with a significantly lower risk of all-cause mortality. A
reduced risk of death was reported with NOACs compared with
VKAs in meta-analyses of RCTs,16,32 although the reduction of
mortality was not significant in some phase 3 trials.15,40 A reduced
risk of death associated with NOAC use compared with VKA use
was inconsistently reported in population-based analyses.33,36 In
our study, the substantially lower risk of major bleeding with NOAC
use was most likely the main driver of the reduction in the risk of all-
cause death, as the rate of death after major bleeding was similar,
irrespective of the OAC in use, at the time of bleeding. The lower
risk of death in NOAC-treated patients cannot be explained by
different baseline characteristics and risk profiles for death and
bleeding between NOAC-treated and VKA-treated subgroups, as
they were similar in both subgroups.
One-third of all deaths in those who had a bleed (78 patients)
occurred the same day as the bleeding, and almost half of all deaths
occurred within the first 30 days, explaining the early abrupt
decrease in the event-free survival curve. Most of these early deaths
occurred after ICH, which had a much worse prognosis than
extracranial major bleeding. ICH accounted for 20% of all deaths at
1 year. Major bleeding was associated with the highest risk of death,
but CRNM and minor bleeding carried a higher risk of death than no
bleeding. After CRNM and minor bleeding, death was rarely related
to bleeding complications but mostly driven by comorbidities, either
cardiovascular (acute coronary syndrome/myocardial infarction,
congestive heart failure [CHF], and sudden death) or noncardio-
vascular (respiratory failure, malignancy, or sepsis). In these
patients, bleeding episodes may be considered as markers rather
than the root cause of the higher risk of death.
Strengths and limitations
This report is based on prospective data collected worldwide that
are representative of real-world practice. Our data are robust, as per
protocol, 20% of all eCRFs were monitored against source
documentation.
Our study did not assess efficacy/safety profile of the different
NOAC subtypes; the steering committee made a decision at the
beginning of the registry not to pursue this question when an RCT
had not been first performed.
We cannot provide detailed information about postbleeding
management. Data on noncardiovascular medications (such as
proton pump inhibitors) were not collected. The severity of bleeding
and cause of death were not independently adjudicated.
Clinical implications
Major bleeding is potentially catastrophic and is associated with
an increased risk of death. Our findings should encourage
clinicians to favor NOACs over VKAs whenever possible. Careful
assessment of the risk of bleeding should be carried out before
introduction of OACs, considering the baseline characteristics of
patients and the information provided by bleeding risk assessment
tools. Combination therapy with OACs plus AP agents should be
avoided when possible, because AP agents are associated with
higher risks of bleeding and ischemic events.3,41 Biological
features that increase bleeding risk, such as low hemoglobin
levels or platelet counts,42,43 and noncardiovascular concurrent
medications that increase bleeding risk should be noted.44 As the
risk of death is also driven by comorbidities and not only by
bleeding, we advocate comprehensive management, targeting
modifiable risk factors such as heart failure, vascular disease,
diabetes, hypertension, and CKD. Minor and CRNM bleeding
should not be considered benign events, as both are associated
with a higher risk of death than no bleeding.
Table 5. Event rates per 100 person-years through 1 year for NOAC6
AP and VKA 6 AP
Type of event
Event rates
NOAC 6 AP VKA 6 AP
Events Rate (95% CI) Events Rate (95% CI)
All-cause mortality 354 3.67 (3.31-4.08) 518 5.51 (5.05-6.00)
Any bleed* 495 5.28 (4.84-5.77) 567 6.23 (5.74-6.76)
Major bleed 127 1.33 (1.11-1.58) 177 1.90 (1.64-2.20)
CRNM bleed 117 1.22 (1.02-1.47) 121 1.30 (1.08-1.55)
Minor 235 2.47 (2.18-2.81) 258 2.79 (2.47-3.15)
ICH 27 0.28 (0.19-0.41) 39 0.41 (0.30-0.57)
*Includes bleeds of unknown types.
Table 6. Unadjusted and adjusted hazard ratio for NOAC 1 AP and
VKA 1 AP (reference group)
Type of event Unadjusted HR (95% CI) P aHR* (95% CI) P
All-cause mortality 0.67 (0.58-0.77) ,.0001 0.73 (0.62-0.85) ,.0001
Any bleed 0.85 (0.75-0.96) .008 0.85 (0.73-0.98) .024
Major bleed 0.70 (0.56-0.88) .002 0.79 (0.60-1.04) .090
CRNM bleed 0.95 (0.73-1.22) .670 0.88 (0.65-1.19) .392
Minor 0.89 (0.75-1.06) .192 0.88 (0.71-1.09) .231
ICH 0.67 (0.41-1.11) .119 0.78 (0.42-1.43) .417
*Adjusted for country of enrolment, cohort of enrolment, sex, age, race/ethnicity, type of
AF, care setting, specialty, heart failure, acute coronary syndromes, vascular disease,
carotid occlusive disease, prior stroke/TIA/SE, prior bleeding, VTE, hypertension, hypercho-
lesterolemia, diabetes, cirrhosis, moderate to severe CKD, dementia, hyperthyroidism,
hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, baseline
systolic and diastolic blood pressure, baseline AP use.
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Conclusions
In patients with AF, use of NOACs rather than VKAs is associated
with lower risks of all-cause death, all bleeding categories, and
major bleeding. Half of all deaths after major bleeding occurred
within the first month (one-third within the first day), pre-
dominantly from intracranial hemorrhage. Major bleeding was
associated with the highest risk of death, and CRNM and minor
bleeding were associated with a higher risk of death than no-
bleeding patients. Underlying comorbidities that also affect the
risk of death warrant comprehensive medical management
of AF.
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